Tirzepatide — Dual GIP/GLP-1 Receptor Agonist (Mounjaro / Zepbound)

Discovery and development

Tirzepatide — catalogued during development as LY3298176 — entered clinical investigation in 2018 following a hypothesis that simultaneously engaging both the glucose-dependent insulinotropic polypeptide (GIP) receptor and the glucagon-like peptide-1 (GLP-1) receptor would produce additive or synergistic metabolic effects beyond those achievable with GLP-1 monotherapy alone [PMID:30473097].

The compound was designed and developed by Eli Lilly and Company. Chemically it is a modified 39-amino-acid peptide with structural homology to native GIP, deliberately engineered to retain high affinity at both incretin receptors while incorporating a C20 fatty diacid moiety attached via a linker to lysine at position 26. This fatty-acid conjugation mirrors the albumin-binding strategy used in semaglutide and is directly responsible for the extended plasma half-life of approximately five days that permits once-weekly subcutaneous dosing [PMID:30473027].

The rationale for dual agonism drew on two decades of physiology research demonstrating that GIP and GLP-1 operate through complementary but non-redundant mechanisms. In individuals with type 2 diabetes, the incretin effect — the augmentation of insulin secretion by gut-derived hormones following oral glucose ingestion — is severely blunted, primarily because the GIP response is impaired. Re-engaging the GIP receptor pharmacologically was therefore expected to partially restore this lost incretin signal while the GLP-1 component provided appetite suppression and gastric slowing [PMID:30473097].

Mechanism of action

Tirzepatide's pharmacology is best understood as the coordinated activation of two distinct G-protein-coupled receptor pathways, each contributing complementary effects on glucose homeostasis, body weight, and metabolic function.

GLP-1 receptor agonism. Activation of the GLP-1 receptor on pancreatic beta cells potentiates glucose-dependent insulin secretion — meaning insulin release is amplified only in the presence of elevated plasma glucose, greatly reducing hypoglycaemia risk compared with insulin or sulfonylureas. GLP-1 receptor stimulation simultaneously suppresses glucagon secretion from alpha cells, further limiting postprandial glucose excursions. In the gastrointestinal tract, GLP-1 receptor activation slows gastric emptying, reducing the rate of nutrient absorption and blunting postprandial glycaemic peaks. Crucially, GLP-1 receptors are expressed on hypothalamic neurons — including the appetite-regulating agouti-related protein (AgRP) and pro-opiomelanocortin (POMC) neurone populations — where agonism promotes satiety signalling, reduces hedonic food-seeking, and decreases total caloric intake [PMID:35658024].

GIP receptor agonism. The GIP receptor contributes an additional glucose-dependent insulin secretion component, particularly during the early postprandial phase. Preclinical evidence from Coskun et al. indicates that GIP receptor co-activation with GLP-1 receptor agonism produces a supra-additive reduction in food intake mediated through distinct hypothalamic circuits [PMID:30473097]. GIP receptor signalling in adipose tissue also appears to improve insulin sensitivity and lipid partitioning, effects that may contribute to tirzepatide's favourable impact on hepatic steatosis observed in clinical subanalyses.

Beta-cell preservation. Thomas et al. demonstrated that twelve weeks of tirzepatide treatment significantly improved beta-cell function indices — including HOMA-B and disposition index — and reduced insulin resistance (HOMA-IR) relative to comparator arms [PMID:33236115]. This suggests the compound may slow progressive beta-cell exhaustion, a key driver of type 2 diabetes progression, beyond its acute glucose-lowering action.

Hypothalamic appetite circuitry. The dual receptor mechanism achieves greater suppression of AgRP neurone activity and stronger POMC neurone activation than GLP-1 agonism alone in rodent models, translating into proportionally greater reductions in caloric intake. This central mechanism is considered the primary driver of the markedly superior weight loss observed in human trials compared with selective GLP-1 agonists.

Researched applications

Tirzepatide has been evaluated across an extensive clinical programme encompassing the SURPASS series (type 2 diabetes) and the SURMOUNT series (obesity), collectively enrolling tens of thousands of participants across multinational phase III trials.

SURMOUNT-1 (obesity without diabetes). Jastreboff et al. enrolled adults with a body-mass index of 30 or above (or 27 with at least one weight-related comorbidity) who did not have type 2 diabetes. At 72 weeks, the group receiving 15 mg once weekly achieved a mean weight reduction of approximately 21% of baseline body weight versus approximately 3% with placebo [PMID:35658024]. More than half of participants receiving the highest dose achieved at least 20% weight reduction. These outcomes exceeded those reported for semaglutide 2.4 mg weekly in the STEP-1 trial and represented a step-change in pharmacological weight management.

SURMOUNT-3 (obesity after lifestyle intervention). Wadden et al. pre-treated participants with an intensive twelve-week lifestyle programme before randomising responders to tirzepatide or placebo. The combined intervention achieved mean weight losses of approximately 26% — suggesting that lifestyle-primed participants derive additional benefit from pharmacotherapy, with tirzepatide maintaining and extending the initial loss [PMID:37872381].

SURPASS-2 (T2DM vs semaglutide). In the head-to-head SURPASS-2 trial, tirzepatide at all three doses (5 mg, 10 mg, and 15 mg weekly) produced significantly greater reductions in HbA1c and body weight than semaglutide 1 mg weekly over 40 weeks [PMID:34170647]. Mean HbA1c reductions ranged from 2.01% to 2.30% for tirzepatide versus 1.86% for semaglutide; mean weight reductions ranged from 7.6 kg to 11.2 kg versus 5.7 kg.

SURPASS-1 (T2DM monotherapy). Rosenstock et al. demonstrated significant HbA1c reductions of up to 2.11% versus 0.01% for placebo in drug-naïve patients with type 2 diabetes across 40 weeks, with approximately 92% of participants at the highest dose reaching HbA1c below 7.0% [PMID:34186126].

SURPASS-3 and SURPASS-5 (insulin-combination contexts). Ludvik et al. found tirzepatide superior to insulin degludec as an add-on to metformin, with substantially lower hypoglycaemia rates [PMID:34370970]. Dahl et al. demonstrated additive glucose lowering and weight benefit when tirzepatide was added to titrated insulin glargine in patients not at goal [PMID:35133415].

Dosing and titration

Licensed clinical titration schedule (Mounjaro/Zepbound). The approved starting dose is 2.5 mg subcutaneously once weekly for four weeks. The dose is then increased in 2.5 mg increments at four-weekly intervals according to tolerability: 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and a maximum of 15 mg once weekly. The slow escalation is explicitly designed to minimise gastrointestinal adverse effects, which are dose- and rate-dependent. Maintenance doses are individualised based on glycaemic or weight targets and tolerability, with no requirement to reach the maximum dose.

Injection site and timing. Tirzepatide is administered subcutaneously into the abdomen, upper arm, or thigh. The day of the week may be changed provided at least three days separate consecutive doses. It may be taken without regard to meals.

Research-protocol context. Investigators using research-grade tirzepatide outside a licensed clinical framework typically mirror the approved titration schedule given the established tolerability rationale, though protocols vary. Dose-finding studies employed 5 mg, 10 mg, and 15 mg as fixed maintenance doses rather than individually titrated endpoints, producing the dose-response relationships reported across the SURPASS and SURMOUNT programmes [PMID:34170647][PMID:35658024].

Missed doses. In the licensed product, if a dose is missed it should be administered as soon as possible within four days of the scheduled date. If more than four days have passed, the missed dose is skipped and the next dose is taken on the usual scheduled day.

Safety profile

Gastrointestinal adverse events. The most common adverse effects across all SURPASS and SURMOUNT trials were nausea, diarrhoea, vomiting, and constipation [PMID:35658024][PMID:34170647]. These were predominantly mild to moderate, occurred most frequently during dose escalation, and diminished with time at stable doses. Rates of discontinuation due to gastrointestinal adverse events in SURMOUNT-1 were approximately 4-5% for active treatment versus less than 1% for placebo. Co-administration with high-fat meals transiently worsens nausea.

Medullary thyroid carcinoma and MEN-2 boxed warning. Tirzepatide carries a class-effect boxed warning shared with all GLP-1 receptor agonists regarding medullary thyroid carcinoma (MTC). Rodent studies demonstrated dose- and duration-dependent thyroid C-cell tumours at pharmacologically relevant exposures; the relevance to humans is unknown but has not been established as absent. Tirzepatide is contraindicated in individuals with a personal or family history of MTC or in those with multiple endocrine neoplasia syndrome type 2 (MEN-2). Prescribers and research protocols should screen for these conditions before initiation.

Pancreatitis. Cases of acute pancreatitis have been reported with GLP-1 receptor agonists as a class. Participants with a history of pancreatitis were excluded from the major tirzepatide trials. The compound should be discontinued if pancreatitis is suspected, and not restarted if confirmed.

Hypoglycaemia. When used as monotherapy or in combination with agents that do not themselves cause hypoglycaemia (metformin, SGLT2 inhibitors), rates of clinically significant hypoglycaemia were very low across trials — consistent with the glucose-dependent mechanism of insulin secretion [PMID:34186126]. Risk is substantially higher with concomitant insulin or sulfonylurea use, where dose reductions of the insulin or sulfonylurea are recommended upon initiation.

Heart rate. A modest increase in resting heart rate of approximately two to four beats per minute has been observed with tirzepatide, consistent with GLP-1 receptor agonist pharmacology. Cardiovascular outcome data from ongoing SURPASS-CVOT are anticipated.

Injection-site reactions. Erythema, pruritus, and nodule formation at injection sites have been reported but are generally mild and transient.

UK regulatory status

Tirzepatide received UK MHRA marketing authorisation under the brand name Mounjaro in November 2023, initially for the treatment of type 2 diabetes mellitus as an adjunct to diet and exercise in adults. A subsequent indication for chronic weight management in adults with obesity (BMI 30 or above) or overweight (BMI 27 or above) with at least one weight-related comorbidity was granted in the UK, aligning Mounjaro with the Zepbound indication approved by the US FDA for Zepbound (the identical active substance marketed under a separate brand for obesity in the United States).

NHS England began rolling out Mounjaro for obesity management through specialist weight management services from 2024, with general prescribing criteria under active development. Private prescriptions are available through registered UK clinicians. The licensed product is formulated as a single-use autoinjector pen (KwikPen) available in 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg strengths.

Research-grade tirzepatide — lyophilised peptide supplied for investigational use — falls entirely outside the licensed product authorisation. It is not a medicinal product and is not subject to the same manufacturing, sterility, and quality standards as Mounjaro. Regulatory frameworks governing its supply, possession, and use for research differ from those applicable to the licensed medicine.

Reconstitution (research-grade vials)

Research-grade tirzepatide is typically supplied as a lyophilised white powder in sealed, multi-dose vials. Because the compound is a relatively large and structurally complex conjugated peptide, careful reconstitution is important to preserve biological activity.

Solvent. Bacteriostatic water for injection (containing 0.9% benzyl alcohol) is the standard diluent for research vials intended for repeat use; it provides antimicrobial protection across multiple draws. Sterile water for injection is appropriate for single-use preparations. The acetate-buffered vehicle used in the licensed autoinjector is not typically reproduced in research-grade preparations.

Volume calculation. Tirzepatide is typically supplied in vials of two to five milligrams. To achieve practical sub-milligram dose increments, reconstituting a two-milligram vial with one millilitre of bacteriostatic water yields a concentration of two milligrams per millilitre; adding two millilitres yields one milligram per millilitre. Lower concentrations ease dose measurement at the low end of the titration schedule.

Technique. Inject the diluent slowly against the vial wall rather than directly onto the lyophilate cake. Swirl gently — do not shake — until the powder is fully dissolved. The solution should be clear and colourless to slightly yellow; discard if particulate matter or unusual colour is present.

Storage. Reconstituted vials should be stored at two to eight degrees Celsius and used within 28 days. The fatty-acid conjugation that extends plasma half-life does not protect against thermal degradation outside this range; freeze-thaw cycles damage the peptide structure and must be avoided. Lyophilised, unreconstituted vials may be stored at room temperature for short periods consistent with manufacturer instructions for research-grade material.

Frequently asked questions

How does tirzepatide differ from semaglutide? Semaglutide (Ozempic/Wegovy) is a selective GLP-1 receptor agonist. Tirzepatide additionally agonises the GIP receptor, which provides a complementary incretin signal, greater hypothalamic appetite suppression, and — in clinical trials — approximately five to seven additional percentage points of mean weight loss compared with semaglutide 1 mg in head-to-head comparison [PMID:34170647]. Indirect comparison with semaglutide 2.4 mg similarly favours tirzepatide, though no published head-to-head trial at those doses has yet completed.

Is tirzepatide suitable for people without diabetes? The SURMOUNT-1 and SURMOUNT-3 trials explicitly enrolled participants without type 2 diabetes and demonstrated the greatest absolute weight reductions in these populations [PMID:35658024][PMID:37872381]. The UK Mounjaro licence includes a weight management indication in non-diabetic individuals meeting BMI criteria.

How long does it take to see weight loss? In SURMOUNT-1, meaningful weight reductions relative to placebo were apparent from the first assessment point at four weeks and continued to diverge throughout the 72-week treatment period, with plateau not clearly reached by trial end at the highest doses, suggesting ongoing efficacy beyond the study window [PMID:35658024].

Can tirzepatide be combined with other weight-management agents? Combination use has not been systematically evaluated in randomised trials outside the insulin add-on context. Research interest in combining tirzepatide with peptides acting through distinct mechanisms — including AOD-9604 for adipose-specific lipolysis or retatrutide for additional glucagon receptor engagement — is growing but currently limited to protocol-level investigation.

What happens if tirzepatide is stopped? Weight regain following discontinuation is well-documented for incretin-based therapies. Participants in SURMOUNT trials who completed the active phase regained a substantial proportion of lost weight within one year of discontinuation, consistent with the pharmacological rather than structural nature of the treatment effect. This underscores the chronic-disease model of obesity treatment.

---

Related stacks

Researchers interested in broader metabolic phenotypes may wish to review the Tirzepatide + Retatrutide + AOD-9604 Metabolic Stack, which outlines how tirzepatide's dual incretin mechanism may complement a triple incretin approach (GLP-1 + GIP + glucagon) alongside the adipose-selective lipolytic activity of AOD-9604.

Source research-grade Tirzepatide

Tirzepatide — Dual GIP/GLP-1 Receptor Agonist (Mounjaro / Zepbound) is sold for laboratory and in vitro research use only. UK regulatory status: UK MHRA licensed (Mounjaro) for type 2 diabetes and obesity. FDA-approved as Mounjaro (T2DM) and Zepbound (chronic weight management). Research-grade material falls outside the licensed product authorisation..

Source on PeptideBarn.co.ukFull monograph on PeptideAuthority.co.uk

References

Peer-reviewed sources for the claims summarised above. Links open PubMed or the journal DOI.

1. Jastreboff AM, Aronne LJ, Ahmad NN, et al. (SURMOUNT-1 Investigators). Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022;387(3) :205-216 doi:10.1056/NEJMoa2206038 · PMID: 35658024
2. Frias JP, Davies MJ, Rosenstock J, et al. (SURPASS-2 Investigators). Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. New England Journal of Medicine. 2021;385(6) :503-515 doi:10.1056/NEJMoa2107519 · PMID: 34170647
3. Rosenstock J, Wysham C, Frias JP, et al. (SURPASS-1 Investigators). Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1). Lancet. 2021;398(10295) :143-155 doi:10.1016/S0140-6736(21)01324-6 · PMID: 34186126
4. Wadden TA, Chao AM, Machineni S, et al.. Tirzepatide after intensive lifestyle intervention in adults with overweight or obesity: the SURMOUNT-3 randomised trial. Nature Medicine. 2023;29(11) :2909-2918 doi:10.1038/s41591-023-02593-1 · PMID: 37872381
5. Coskun T, Sloop KW, Loghin C, et al.. LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: from discovery to clinical proof of concept. Molecular Metabolism. 2018;18 :3-14 doi:10.1016/j.molmet.2018.09.009 · PMID: 30473097
6. Dahl D, Onishi Y, Norwood P, et al. (SURPASS-5 Investigators). Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes: The SURPASS-5 Randomized Clinical Trial. JAMA. 2022;327(6) :534-545 doi:10.1001/jama.2022.0078 · PMID: 35133415
7. Thomas MK, Nikooienejad A, Bray R, et al.. Dual GIP and GLP-1 Receptor Agonist Tirzepatide Improves Beta-cell Function and Insulin Sensitivity in Type 2 Diabetes. Journal of Clinical Endocrinology and Metabolism. 2021;106(2) :388-396 doi:10.1210/clinem/dgaa863 · PMID: 33236115
8. Ludvik B, Giorgino F, Jódar E, et al. (SURPASS-3 Investigators). Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3). Lancet. 2021;398(10300) :583-598 doi:10.1016/S0140-6736(21)01443-4 · PMID: 34370970